DevelopmentTargeting the C5a pathway in HS has failed to generate positive data in two separate randomized, placebo-controlled studies.
Financial PerformanceInflaRx reported revenues of €0.0M in 1Q24, compared to an estimate of €0.1M.
RisksRisks include commercial, regulatory, development, manufacturing, financial, and liability concerns.